Cardio Diagnostics Holdings (CDIO) FCF Margin (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted FCF Margin of 58357.16% for Q1 2026, down 52.34% sequentially from 38307.99% in Q4 2025, and up 9120539.0% YoY from N/an in Q1 2025.
Cardio Diagnostics Holdings (CDIO) FCF Margin (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported FCF Margin for 5 years, with the latest figure at 58357.16% in Q1 2026.
- Quarterly FCF Margin rose 9120539.0% year-over-year to 58357.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36657.01% (down 972142.0% YoY) and the FY2025 annual result came in at 39893.09%, down 2496655.0% from the prior year.
- FCF Margin declined to 58357.16% in Q1 2026 per CDIO's latest filing, from 38307.99% in the prior quarter.
- Over five years, FCF Margin peaked at 7866.87% in Q1 2024 and troughed at 348309.37% in Q4 2022.
- A 5-year average of 65925.3% and a median of 38307.99% in 2025 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2025: FCF Margin soared 30645005 bps in 2023, then tumbled 14169568 bps in 2025.
- Over 5 years, FCF Margin stood at 348309.37% in 2022, then surged by 88 bps to 41859.32% in 2023, then rose by 26 bps to 30938.23% in 2024, then decreased by 24 bps to 38307.99% in 2025, then sank by 52 bps to 58357.16% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 58357.16%, 38307.99%, and 54509.7% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Cardio Diagnostics Holdings | 6.42 Mn | 835,350.96 | - | -25,044.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25,044.10% |
| Mar 31, 2026 | -58,357.16% |
| Dec 31, 2025 | -38,307.99% |
| Sep 30, 2025 | -54,509.70% |
| Jun 30, 2025 | -21,273.06% |
| Mar 31, 2025 | -149,562.55% |
| Dec 31, 2024 | -30,938.23% |
| Sep 30, 2024 | -17,942.33% |
| Jun 30, 2024 | -17,513.29% |
| Mar 31, 2024 | -7,866.87% |
| Dec 31, 2023 | -41,859.32% |
| Sep 30, 2023 | -10,540.28% |
| Jun 30, 2023 | -60,048.75% |
| Dec 31, 2022 | -348,309.37% |